Supporting data for “INVESTIGATION ON THE PATHOGENESIS AND NOVEL INTERVENTION TARGETS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION”

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in late 2019 and rapidly disseminated globally. Despite being similar in their genomic compositions and the ability to cause pneumonia, SARS-CoV-2 and SARS-CoV-1 differ in their capability to cause extrapulmonary (such as neurological and gastrointestinal) manifestations. Importantly, the mortality rate of COVID-19 has been generally less than that of SARS. The virological characteristics of SARS-CoV-2 that contribute to these clinical differences were unknown at the early stage of the pandemic.
In Chapter 2, the differential cellular susceptibilities, replication kinetics, and cell damage profiles of SARS-CoV-2 and SARS-CoV-1 were systematically investigated in 25 different cell lines. SARS-CoV-2 infected and replicated to comparable levels in human Calu3 (lung) and Caco2 (colon) cells, whereas SARS-CoV-1 replicated more efficiently in Caco2 cells than in Calu3 cells (P

严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）于2019年底首次出现，并迅速在全球范围内传播。尽管在基因组组成和引发肺炎的能力上与SARS-CoV-1相似，但SARS-CoV-2与SARS-CoV-1在引起肺外（如神经系统和消化系统）表现方面存在差异。值得注意的是，COVID-19的死亡率总体上低于SARS。在疫情初期，导致这些临床差异的SARS-CoV-2病毒学特征尚不为人知。
在第二章中，对SARS-CoV-2和SARS-CoV-1在不同细胞系中的差异细胞敏感性、复制动力学和细胞损伤特征进行了系统的探究，涉及25种不同的细胞系。SARS-CoV-2在人类Calu3（肺）和Caco2（结肠）细胞中的感染和复制水平相当，而SARS-CoV-1在Caco2细胞中的复制效率高于在Calu3细胞中（P值未给出）。